Alvimedica, officially unveiled the details of the Diab8 study, the first diabetic Drug-Eluting Stent (DES) randomized trial, during the Annual Meeting of EuroPCR 2018.
A global manufacturer of unique interventional medical devices, harnessing the power of innovation to improve our patient’s quality of life. We tackle today’s toughest patients clinical conditions by creating innovative products.
We create the highest quality products, trusted by leading professionals around the world.
Our driving passion is to improve the quality of life through innovative technology, creating a better future by investing in both clinical research and product development.
Alvimedica is committed to improving patient outcomes, as well as tackling global issues such as Diabetes, which we are 100% committed to defeating.
Polymer-free Amphilimus™ (Sirolimus + Fatty acid) eluting coronary stent.
The only very effective polymer-free DES, just got better
Polymer-free Amphilimus eluting stent for below the knee arteries.
Diabetes is a number of diseases that involve
problems with hormone insulin.
Alvimedica, officially unveiled the details of the Diab8 study, the first diabetic Drug-Eluting Stent (DES) randomized trial, during the Annual Meeting of EuroPCR 2018
Istanbul, Turkey, October 19, 2017- Alvimedica, global medical technologies group, pleased to announce taking the first step for the opening of its third factory, the newest production facility, located in Çatalca, Istanbul.